# Ansa Biotechnologies, Inc.: Research, Emeryville, United States

> Ansa Biotechnologies, Inc.: Ansa Biotechnologies, Inc. Based in Emeryville, United States. Founded 2018.

Source: https://millionrounds.com/startup/ansa-biotechnologies-inc (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Ansa Biotechnologies, Inc.

Ansa Biotechnologies, Inc.

Funding reported Last round: Series A

Research Emeryville, United States

Company summary

- **Founded:** 2018 8 years old
- **Team:** 81 51 to 200 people
- **Funding reported:** $83M in dollars
- **Last round:** Series A Apr 2022

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Ansa Biotechnologies, Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Ansa Biotechnologies, Inc.

Ansa Biotechnologies, Inc.

is a biotechnology company based in Emeryville, California, focused on developing and commercializing next-generation enzymatic DNA synthesis technology. Founded in 2018 as a spin-out from the Joint BioEnergy Institute and UC Berkeley, Ansa aims to transform the DNA manufacturing industry by introducing a faster and more accurate enzyme-based approach to DNA synthesis. The company has raised approximately $82.7 million in funding and employs around 70–77 people. Ansa operates primarily as a B2B service provider, offering made-to-order synthetic DNA. Their services include the synthesis of gene-length DNA molecules directly from customer-submitted sequences, with a transparent per-base-pair pricing model and an on-time delivery guarantee. Key products include the 50 kilobase clonal DNA product, which is the longest sequence-perfect synthetic DNA available, and a robust enzymatic DNA synthesis platform. Ansa serves various sectors, including pharmaceuticals, gene therapy, synthetic biology, and agricultural biotechnology, providing essential DNA building blocks for research and development.

## What company datasets say Ansa Biotechnologies, Inc. raised

Funding, as reported

Reported in all **$83M** in dollars

Rounds **6**

Last round **Series A**

Last round size **$54M**

Last round date **Apr 2022**

Investors listed **15**

Y Combinator **W20**

## Founders and team

From Ansa Biotechnologies, Inc.'s own website: 2 founders, 6 on the team.

**Dan Lin-Arlow** Chief Scientific Officer and co-founder

**Sebastian Palluk** Chief Technology Officer and co-founder

- **Jason T. Gammack** Chief Executive Officer
- **Dave Bullis** Vice President, Strategic Marketing
- **Evan King** Vice President, Sales
- **John Trust** Vice President, Finance
- **Nick Hurt** Vice President, Legal
- **Geoff Hamilton** Chief Financial Officer and Chief Business Officer

## On 3 portfolio pages

Investors who name them

- [Carbon Silicon Ventures](https://millionrounds.com/fund/carbon-silicon-ventures)
- [Dauntless Ventures](https://millionrounds.com/fund/dauntless-ventures)
- [Synergenics](https://millionrounds.com/fund/synergenics)

Each firm lists Ansa Biotechnologies, Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

long dna sequences health care dna synthesis technology gene therapy vectors promoters custom gene synthesis biotechnology research clonal dna products long dna strands manufacturing healthcare complex promoter sequences crispr applications high gc content dna utrs biotech innovations

Built with from their website

NetSuite Salesforce Marketing Cloud Account Engagement Resi AMP CloudFlare CDN Google Tag Manager Apex DoubleClick Priority Hints CAPTCHA

+8 more

Google Font API Mailcheck Tableau REST Graphy punycode WordPress.org JupyterHub

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 3829
- **Region:** California
- **Revenue:** $9.0M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/ansa-biotechnologies)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Ansa Biotechnologies, Inc. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)